Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies
Diamond, B.; Chahar, D.; Jain, M. D.; Poos, A. M.; Durante, M.; Ziccheddu, B.; Kaddoura, M.; Papadimitriou, M.; Maclachlan, K. H.; Jelinek, T.; Davies, F.; Figura, N. B.; Morgan, G.; Mai, E.; Weisel, K. C.; Fenk, R.; Raab, M. S.; Usmani, S.; Landgren, O.; Locke, F. L.; Goldschmidt, H.; Schatz, J. H.; Weinhold, N.; Maura, F.
Show abstract
Ionizing radiotherapy (RT) is a widely used palliative and curative treatment strategy for malignancies. In solid tumors, RT-induced double strand breaks lead to the accumulation of indels, and their repair by non-homologous end-joining has been linked to the ID8 mutational signature in resistant cells. However, the extent of RT-induced DNA damage in hematologic malignancies and its impact on their evolution and interplay with commonly used chemotherapies has not yet been explored. Here, we interrogated 580 whole genome sequencing (WGS) from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet, it was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose-response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode we demonstrate that a single RT-resistant cell may seed systemic relapse.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.